News Release

Smokers' COPD risk is genetic

Peer-Reviewed Publication

BMC (BioMed Central)

It's well known that puffing on cigarettes can eventually leave you out of puff. But why do a quarter of long-term smokers develop serious breathing problems, when others do not? New research published BioMed Central's open access journal Respiratory Research has found that the answers may lie in a smoker's genetics, which affect their chances of developing chronic obstructive pulmonary disease (COPD) in later life.

US-based researchers Alireza Sadeghnejad, Jill Ohar, Eugene Bleecker and colleagues from the Wake Forest School of Medicine and Saint Louis University, looked at a disintegrin and metalloprotease (ADAM) gene known as ADAM33 in 880 long-term heavy smokers. Located on chromosome 20, ADAM33 has been linked with asthma in previous studies. This new study is unique in comparing long-term smokers with COPD versus a control group of long-term smokers without COPD.

The researchers found five single nucleotide polymorphisms (SNPs) – human DNA sequence variations - in ADAM33 that were more frequent in the COPD group than in the group of smokers without COPD. One SNP, known as S1, had a particularly strong link to lung abnormalities. "Functional studies will be needed to evaluate the biologic significance of these polymorphisms in the pathogenesis of COPD," according to the authors.

COPD is characterized by progressive decline in lung function, and encompasses chronic bronchitis and emphysema. Almost 90% of COPD is caused by long-term cigarette smoking, yet only 25% of chronic tobacco smokers will go on to develop COPD.

###

Notes to Editors:

1. Adam33 polymorphisms are associated with COPD and lung function in long term tobacco smokers
Alireza Sadeghnejad, Jill A Ohar, Siqun L Zheng, David A Sterling, Gregory A Hawkins, Deborah A Meyers and Eugene R Bleecker
Respiratory Research (in press)

During embargo, article available here: http://respiratory-research.com/imedia/2042246055212423_article.pdf?random=766308

After the embargo, article available at the journal website: http://respiratory-research.com/

Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.

Article citation and URL available on request at press@biomedcentral.com on the day of publication.

2. Respiratory Research is an Open Access, peer-reviewed, online journal that considers manuscripts on all aspects of respiratory function and disease.

The journal welcomes studies on asthma, chronic obstructive pulmonary disease, cystic fibrosis, genetics, infectious diseases, interstitial lung diseases, lung development, lung tumors, occupational and environmental factors, pulmonary circulation, pulmonary pharmacology and therapeutics, respiratory critical care, respiratory immunology, respiratory physiology, and sleep. The journal will also welcome state-of-the-art reviews on related topics.

3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.